Company news

Summit Therapeutics Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112)

May 8, 2023

Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (SMT112)

May 2, 2023

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022

March 8, 2023

Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering

March 2, 2023

Summit Therapeutics’ Rights Offering Nearing Expiration Date

February 22, 2023

Summit Therapeutics Announces Timing for Rights Offering for Up to $500 Million

January 29, 2023

Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody

January 19, 2023

Summit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 4, 2023

Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody

December 5, 2022

Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of Directors

November 16, 2022

Summit Therapeutics Inc. Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2022

November 8, 2022

Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022

October 19, 2022

Summit Therapeutics to Present Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022

October 12, 2022

Summit Therapeutics Appoints Dr. Robert Booth, Renowned Executive and Scientific Leader, to its Board of Directors

October 2, 2022

Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2022

August 10, 2022

Summit Therapeutics Closes Fully-Subscribed $100 Million Rights Offering

August 8, 2022

Summit Therapeutics Appoints Dr. Maky Zanganeh as Co-CEO & President

July 25, 2022

Summit Therapeutics Announces Commencement of $100 Million Rights Offering

July 17, 2022

Summit Therapeutics Provides Update on Ridinilazole

July 13, 2022

Summit Therapeutics Announces $100 Million Rights Offering

June 21, 2022

Summit Therapeutics’ Upcoming Annual Shareholders’ Meeting

June 2, 2022

Summit Therapeutics Appoints Ankur Dhingra as Chief Financial Officer

May 31, 2022

Summit Therapeutics Inc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2022

May 10, 2022

Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2021

March 16, 2022

Summit Therapeutics Announces Postponement of Its Planned Rights Offering

February 8, 2022

Summit Therapeutics Announces Rights Offering

January 24, 2022

Summit Therapeutics Today Presents Its Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference

January 9, 2022

Summit Therapeutics to Present Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference

January 4, 2022

Summit Therapeutics Announces Topline Results for Phase III Ri-CoDIFy Study for C. Difficile Infection

December 19, 2021

Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2021

November 14, 2021

Summit Therapeutics Bolsters Its Board of Directors with Seasoned Regulatory & Clinical Research Executive Dr. Urte Gayko

November 2, 2021

Summit Therapeutics Appoints Prominent Biotech Attorney and Advisor Kenneth A. Clark to Its Board of Directors

October 7, 2021

Summit Therapeutics Presents Further Breakthrough Insights Surrounding the Novel Mechanism of Action for its Investigational Drug Ridinilazole During IDWeek 2021

September 29, 2021

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2021

August 10, 2021

Summit Therapeutics Provides Update on Ri-CoDIFy Trials

August 10, 2021

Summit Therapeutics Presents Breakthrough Research Data from Phase II Studies, including Evidence Validating Microbiome Preservation, for its Investigational Drug Ridinilazole

July 11, 2021

Summit Therapeutics to Present Breakthrough Research Updates at the 31st Annual ECCMID Conference, including a Top-Rated ePoster

June 30, 2021

Summit Therapeutics set to join Russell 3000® Index

June 7, 2021

Summit Therapeutics Announces Preclinical Candidate and Associated CARB-X Funding Support for the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae, a CDC Urgent Threat and WHO Critical Priority

May 17, 2021

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2021

May 16, 2021

Summit Therapeutics Announces Closing of $75 Million Rights Offering

May 11, 2021

Summit Therapeutics Publishes Scientific Updates to Corporate Website

May 5, 2021

Summit Therapeutics’ Rights Offering Nearing Expiration Date; Robert W. Duggan Declares Intention to Fully Oversubscribe in the Rights Offering

May 4, 2021

Summit Therapeutics Announces Commencement of Rights Offering

April 20, 2021

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2020

March 16, 2021

Summit Therapeutics Appoints Dr. Mahkam (“Maky”) Zanganeh as Chief Operating Officer

November 22, 2020

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2020

November 15, 2020

Summit Announces Closing of Private Placement of $50 Million

November 5, 2020

Summit Announces Agreement For a Fundraising of approximately $50 Million

October 1, 2020

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2020

September 28, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 11 calls. Every call is listed under its year.

Decks

The 5 newest of 32 decks. Every deck is listed under its year.